CN

About Us

Healsun Biopharm started its journey by providing stable cell line construction services and has gradually expanded its scope of services to one-stop R&D and production solution for antibodies, fusion proteins, and ADC products from early druggability evaluation, IND pharmaceutical research to commercial production.


After years of dedicated efforts, we have garnered the trust and loyalty of numerous esteemed clients through our excellent service and reputation. We aspire to become a leading CDMO service provider, aiming to provide our clients with the highest quality solutions and support them in achieving remarkable accomplishments in the field of drug development.

Early-Stage Development
Cell Line Development
Biologics and ADC Process Development
IND Files Preparation and Applicaton
GMP Pilot Production
PC/PV
GMP Commercial Production
Media Development & Customization

  • R&D Center

    Providing clients with comprehensive molecular design and evaluation service, such as protein engineering, activity analysis and druggability analysis based on our high-quality protein production platforms and multiple analytical tools


  • R&D Center

    Self-developed HaoYue® Platform, which can deliver sublicensable stable cell lines with high expression

    Process development platforms


  • Production Plant

    2*250 L/500 L GMP manufacturing lines for DS and DP

    100 L GMP manufacturing line for ADC DS


  • Production Site(put into use in 2024)

    6*2000 L commercial-scale manufacturing lines for antibodies

    500 L commercial-scale manufacturing line for ADC products

2015

Founded

52500

Area

4

Sites

250+

Employees

Development History



Nov.11

Founded


2015
2018

Aug.08

1st CLD Project Obtained IND Approval


Dec.12

Strategic Investment Obtained




Jun.06

New Headquarters Put into Use





2019
2021

Mar.03

Series A Round Completed

1st One-Stop Solution Project Obtained IND Approval


Nov.11

MFG1 Put into Use



Aug.08

Series B Round Completed




2022
2023

Oct.10

Series B+ Round Completed





Q4

MFG2 40000m²

Put into Use




2024
Future